Yes. Thanks for taking my question. Sir, on this domestic business growth of 10.5%, which we have seen during the quarter, can you comment in terms of what was the organic growth for the portfolio excluding the Sanofi oral anti-diabetes brands?
Okay. So and this quarter, you would have seen the, let's say, contribution from the diabetes portfolio to the extent of 2 months?
Yes. Sir, in Nashik, there has been a significant delay in terms of ramp-up. So it has been almost now 1.5, 2 years since we commissioned that hospital, and we are still incurring losses there. So where do you think that ramp-up in Nashik has been, let's say, slower versus our expectations versus what we have been able to achieve in Thane or even the first Bangalore hospital?
Sure, Dr. Abhinay. So if we get the CGHS license in Nashik, then obviously, with the revised rates on the CGHS business, post that, Nashik should see a good ramp-up?
Sir, on this Pune greenfield hospital, which we have, let's say, focused on now, what led to you deciding Pune as a market within the West India market? So can you talk about in terms of the market potential within Pune and are you choosing Pune for your West India foray?
Sure, sir. And sir, what kind of capex would we be incurring for this 150-bed greenfield hospital?